Literature DB >> 24448453

Managing the innovation supply chain to maximize personalized medicine.

S A Waldman1, A Terzic2.   

Abstract

Personalized medicine epitomizes an evolving model of care tailored to the individual patient. This emerging paradigm harnesses radical technological advances to define each patient's molecular characteristics and decipher his or her unique pathophysiological processes. Translated into individualized algorithms, personalized medicine aims to predict, prevent, and cure disease without producing therapeutic adverse events. Although the transformative power of personalized medicine is generally recognized by physicians, patients, and payers, the complexity of translating discoveries into new modalities that transform health care is less appreciated. We often consider the flow of innovation and technology along a continuum of discovery, development, regulation, and application bridging the bench with the bedside. However, this process also can be viewed through a complementary prism, as a necessary supply chain of services and providers, each making essential contributions to the development of the final product to maximize value to consumers. Considering personalized medicine in this context of supply chain management highlights essential points of vulnerability and/or scalability that can ultimately constrain translation of the biological revolution or potentiate it into individualized diagnostics and therapeutics for optimized value creation and delivery.

Entities:  

Mesh:

Year:  2014        PMID: 24448453     DOI: 10.1038/clpt.2013.228

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Reply: Translation of regenerative technologies into clinical paradigms.

Authors:  Atta Behfar; Ruben Crespo-Diaz; Andre Terzic; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2014-08-05       Impact factor: 32.419

2.  Big Data Transforms Discovery-Utilization Therapeutics Continuum.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2016-03       Impact factor: 6.875

3.  Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer.

Authors:  Delmy Oliva; Mats Nilsson; Bengt-Åke Andersson; Lena Sharp; Freddi Lewin; Nongnit Laytragoon-Lewin
Journal:  Clin Transl Radiat Oncol       Date:  2016-12-27

Review 4.  Regenerative Medicine Build-Out.

Authors:  Andre Terzic; Michael A Pfenning; Gregory J Gores; C Michel Harper
Journal:  Stem Cells Transl Med       Date:  2015-11-04       Impact factor: 6.940

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.